Navigation Links
New discovery could lead to vaccines for plague and bacterial pneumonias
Date:1/25/2011

Saranac Lake, N.Y. There is an ongoing battle in the "war on terror" that remains mostly unseen to the public -- a race between scientists working to develop a vaccine to protect against plague and the terrorists who seek to use plague as a weapon.

"Governments remain concerned that bioweapons of aerosolized Yersinia pestis, the bacteria that causes plague, could kill thousands," said Stephen Smiley, a leading plague researcher and Trudeau Institute faculty member.

The anthrax scare that followed the terror attacks of September 11, 2001, made the threat of bioterrorism real and led to a surge in federal funding into research aimed at heading off such threats.

According to Dr. Smiley, there is no licensed plague vaccine in the United States. Together with postdoctoral associate Jr-Shiuan Lin, he is working to develop a vaccine that will protect members of the armed services and public from a "plague bomb."

Yersinia pestis is arguably the most deadly bacteria known to man. Plague infections of the lung, known as pneumonic plague, are extremely lethal. The bacteria, which grow both inside and outside the cells of the lung, usually lead to death within a week of infection.

Most of the plague vaccine candidates that have been studied aim to stimulate B cells to produce plague-fighting antibodies. However, animal studies suggest that antibodies may not be enough to protect humans from pneumonic plague. The Smiley laboratory has shown that T cells can also fight plague. The lab previously demonstrated that a single immunization with an experimental vaccine stimulates the production of T cells that provide partial protection against pneumonic plague.

New data, reported in the current issue of The Journal of Immunology, show that a second immunization, or booster, improves the protection provided by T cells. "It is particularly exciting that the boost seems to improve protection by increasing a newly described type of T cell, which we call a Th1-17 cell," said Dr. Smiley. These cells have characteristics of both Th1 cells, which defend against intracellular bacteria, and Th17 cells, which specialize at killing extracellular threats.

This research is focused primarily on thwarting the use of plague as a bioweapon. However, small, natural outbreaks of plague continue to this day. A plague vaccine will protect against both naturally occurring outbreaks and those that have been manufactured.

Additionally, Dr. Smiley believes these Th1-17 cells may be important in fighting other kinds of pneumonia: "Bacterial pneumonia is one of the most common causes of death in hospitals and, like plague, many of these pneumonias are caused by bacteria that grow both inside and outside the cells of our bodies."


'/>"/>

Contact: Brian Turner
bturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related medicine news :

1. UCSF Enters Drug Discovery Agreement with Genentech
2. UCSF enters drug discovery agreement with Genentech
3. New discovery: Plaice are spotted (on the inside)
4. SeqWright Advances Genomic Discovery With Isilon IQ
5. Effective prostate cancer treatment discovery
6. Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma
7. U discovery gives insight into brain replay process
8. Discovery of cellular switch may provide new means of triggering cell death, treating disease
9. Discovery May Lead to Better Multiple Sclerosis Treatments
10. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
11. TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New discovery could lead to vaccines for plague and bacterial pneumonias
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... ... an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for ... not-for-profit Catholic health care system that’s partnering with Intel on value-based health benefits ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical Systems, ... with highly adaptable algorithms, has been updated to help Emergency Department physicians and ... consistent with Zikas and a travel history to affected regions, or potential exposure ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... call for nominations seeking candidates for the Board of Commissioners. Individuals interested in ... skills and experience with diversity of clinical practice settings and across allied health ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you back from ... poses a question as a challenge for his readers to examine the full ... Being" (published by Partridge Singapore), Clarke explores the subject with more depth, revealing ...
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , one of this ... A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the round was intended ...
(Date:2/11/2016)... CARLSBAD, Calif. , Feb.11, 2016  Ionis Pharmaceuticals, Inc. ... a live webcast on Thursday, February 25 at 11:30 a.m. ... on pipeline and business progress. www.ionispharma.com . ... at the same address. --> www.ionispharma.com . A ... the same address. --> Interested parties may listen ...
(Date:2/11/2016)... -- Indiso ltd , a medical technology company ... respiratory diseases announced today positive results in its clinical ... patients show improvements in respiratory functions and other clinical ... Upper and lower respiratory tract diseases and allergy ... reached epidemic level. Increasing number of studies however show ...
Breaking Medicine Technology: